Reactome | CHRM1,3,5 bind CHRM1,3,5 antagonists

CHRM1,3,5 bind CHRM1,3,5 antagonists

Stable Identifier

R-HSA-9704151

Type

Reaction [binding]

Species

Homo sapiens

Compartment

plasma membrane, extracellular region

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

Signal Transduction (Homo sapiens)

- Signaling by GPCR (Homo sapiens)
  - GPCR ligand binding (Homo sapiens)
    - Class A/1 (Rhodopsin-like receptors) (Homo sapiens)
      - Amine ligand-binding receptors (Homo sapiens)
        
        Muscarinic acetylcholine receptors (Homo sapiens)
        
        CHRM1,3,5 bind CHRM1,3,5 antagonists (Homo sapiens)

General

SBML | | PDF

SVG | | PPTX | SBGN

Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

A muscarinic receptor (CHRM) antagonist is a type of anticholinergic agent that blocks the activity of human muscarinic acetylcholine receptors 1-5 (Caulfield & Birdsall 1998, Dorje et al. 1991, Bolden & Richelson 1992). Muscarinic antagonists reduce the activation of the parasympathetic nervous system. The normal function of the parasympathetic system is often described as "rest-and-digest", and includes slowing of the heart, narrowing of airways, an increased digestion rate, promotion of urination, and sexual arousal. Most muscarinic antagonists are synthetic but two of the most commonly used ones are belladonna alkaloids (from deadly nightshade plants), namely scopolamine and atropine. Scopolamine is used to treat motion sickness (Golding & Gresty 2015) whereas atropine can counter organophosphate poisoning (Bajracharya et al. 2016). Both are used for comsetic purposes to promote pupil dilation (Tran et al. 2018).

Muscarinic antagonists are widely used in the treatment of low heart rate (Harvey 2012), overactive bladder (Nadeau et al. 2014, Franco et al. 2020), peptic and gastric ulcers (Ehlert et al. 2012, Shamburek & Schubert 1993), asthma and COPD (Alagha et al. 2014), and neurological problems such as Parkinson's disease (Ztaou & Amalric 2019) and Alzheimer's disease (Clader & Wang 2005).

Literature References

PubMed ID	Title	Journal	Year
22222706	Muscarinic agonists and antagonists: effects on gastrointestinal function Pak, KJ, Ehlert, FJ, Griffin, MT	Handb Exp Pharmacol	2012
1994002	Antagonist binding profiles of five cloned human muscarinic receptor subtypes Brann, MR, Tacke, R, Wess, J, Dörje, F, Lambrecht, G, Mutschler, E	J. Pharmacol. Exp. Ther.	1991
25502048	Pathophysiology and treatment of motion sickness Gresty, MA, Golding, JF	Curr Opin Neurol	2015
8097411	Pharmacology of gastric acid inhibition Shamburek, RD, Schubert, ML	Baillieres Clin Gastroenterol	1993
9647869	International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors Birdsall, NJ, Caulfield, MP	Pharmacol Rev	1998
32007426	Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies Vande Walle, J, Bosman, B, Dahler, E, Davies, LN, Snijder, R, Hoebeke, P, Franco, I, Bolong, D, Stroosma, O, Verheggen, F, Baka-Ostrowska, M, Newgreen, D	J Pediatr Urol	2020
29715053	A Review of Myopia Control with Atropine Tran, YH, Jong, M, Tran, TD, Coroneo, M, Sankaridurg, P, Tran, HDM	J Ocul Pharmacol Ther	2018
24839481	Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study Pellerin, E, Lamontagne, P, Nadeau, G, Moore, K, Schröder, A, Genois, L, Hamel, M, Bolduc, S	Can Urol Assoc J	2014
28327676	Management of Organophosphorus Poisoning Bajracharya, SR, Prasad, PN, Ghimire, R	J Nepal Health Res Counc	2016
1346637	Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells Cusack, B, Bolden, C, Richelson, E	J. Pharmacol. Exp. Ther.	1992
24587893	Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases Chanez, P, Martinez, S, Sofalvi, T, Alagha, K, Tummino, C, Pahus, L, Charpin, D, Bourdin, A, Palot, A, Gouitaa, M	Ther Adv Chronic Dis	2014
16250841	Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease Clader, JW, Wang, Y	Curr Pharm Des	2005
30825602	Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson's disease Amalric, M, Ztaou, S	Neurochem Int	2019
22222704	Muscarinic receptor agonists and antagonists: effects on cardiovascular function Harvey, RD	Handb Exp Pharmacol	2012